Log in or Sign up for Free to view tailored content for your specialty!
Gastrointestinal Cancer News
Increased cancer burden in older adults with type 2 diabetes over past 20 years
Cancer burden among older adults with type 2 diabetes has increased in the past 2 decades while all-cause mortality rates at all ages have decreased, according to a 20-year population-based study published in Diabetologia.
Stereotactic body radiation extends survival in hepatocellular carcinoma
Stereotactic body radiation therapy followed by sorafenib extended survival compared with sorafenib alone among patients with hepatocellular carcinoma, according to study results presented at ASCO Gastrointestinal Cancers Symposium.
Log in or Sign up for Free to view tailored content for your specialty!
Use of antibiotics safe during durvalumab-based treatment for biliary tract cancer
Patients with advanced biliary tract cancer can safely use antibiotics while benefiting from treatment with durvalumab plus gemcitabine and cisplatin, according to study results presented at ASCO Gastrointestinal Cancers Symposium.
Long-course chemoradiation may improve organ preservation rates in rectal cancer
A long course of chemoradiation therapy appeared associated with higher organ preservation rates vs. a short course among a cohort of patients with rectal cancer, according to a study presented at ASCO Gastrointestinal Cancers Symposium.
Trifluridine/tipiracil plus bevacizumab prolongs survival in refractory colorectal cancer
The addition of bevacizumab to trifluridine/tipiracil demonstrated a statistically significant and clinically meaningful improvement in OS vs. trifluridine/tipiracil alone among adults with refractory metastatic colorectal cancer.
Follow-up colonoscopy rates after positive colorectal cancer screening result are low
Many patients who received a positive stool-based screening test result for colorectal cancer did not receive a follow-up colonoscopy within 1 year, according to the results of a mixed-methods cohort study.
Tislelizumab regimen new first-line option for gastric, gastroesophageal cancer subgroup
Tislelizumab plus chemotherapy demonstrated statistically significant and clinically meaningful improvements in OS vs. chemotherapy alone among patients with PD-L1-positive, advanced gastric or gastroesophageal junction adenocarcinoma.
The Wistar Institute names cancer center deputy director
Maureen E. Murphy, PhD, has been appointed deputy director of Ellen and Ronald Caplan Cancer Center at The Wistar Institute.
Zolbetuximab benefits subset of patients with gastric, gastroesophageal junction cancer
First-line treatment with zolbetuximab added to chemotherapy significantly extended OS and PFS among adults with certain forms of claudin-18.2-positive/HER2-negative gastric adenocarcinoma, results of the phase 3 SPOTLIGHT trial showed.
Mark Lewis, MD, discusses career motivation, Twitter and oncology’s emotional ‘yin-yang’
Mark A. Lewis, MD, has two special drawers in his office desk — one with notes of appreciation he has received from patients over the years and the other with his patients’ obituaries.
-
Headline News
FDA approves nasal spray as first self-administered flu vaccine
September 20, 20241 min read -
Headline News
HHS proposes rule change for HIV-positive organ recipients
September 23, 20241 min read -
Headline News
Cold weather exposure may increase risk for heart attack
September 23, 20242 min read
-
Headline News
FDA approves nasal spray as first self-administered flu vaccine
September 20, 20241 min read -
Headline News
HHS proposes rule change for HIV-positive organ recipients
September 23, 20241 min read -
Headline News
Cold weather exposure may increase risk for heart attack
September 23, 20242 min read